VITPSO
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Explore 59 assets in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma →Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Columbia University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05680558CT.gov Photopheresis in Early-stage Mycosis Fungoides | — | Recruiting | — | — | — |
NCT03563040CT.gov Study of Photopheresis in the Treatment of Erythrodermic MF and SS | — | Withdrawn | — | — | — |
NCT00221039CT.gov Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| VITPSO (this asset) | Columbia University | Approved | BB · 67 |
| (+)-Vincristine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Cyclophosphamide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Bexarotene | Case Comprehensive Cancer Center | P4 | BBB |
| Dexasone | National Cancer Institute (NCI) | P2 | BBB |
| Adriamycin | Falo, Louis, MD | P4 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BBB |
| Nivestim | City of Hope Medical Center | P4 | BBB |
| Etoposide | City of Hope Medical Center | P2 | BB |
+42 more in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort
Other indications for VITPSO
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BB · 67 |
| Acquired Epidermolysis Bullosa | — | P2 | B · 57 |
| Lymphoma | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. VITPSO in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vitpso-primary-cutaneous-t-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →